2020
DOI: 10.1080/2000656x.2020.1781141
|View full text |Cite
|
Sign up to set email alerts
|

Complications in skin grafts when continuing antithrombotic therapy prior to cutaneous surgery requiring skin grafting: an observational study

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
8
0

Year Published

2022
2022
2023
2023

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(8 citation statements)
references
References 18 publications
0
8
0
Order By: Relevance
“…Of the 13 articles, four were prospective observational cohort studies, one was a retrospective case-control study, and the remaining eight were retrospective observational cohort studies (Appendix S1). [15][16][17][18][19][20][21][22][23][24][25][26][27] Over 12 years, there were 10,750 patients who underwent cutaneous surgery, with 1,312 of them performed on patients prescribed a DOAC. The mean participant age ranged from 68 to 78.8 years of age, with a male predominance (49.9-81.8%).…”
Section: Resultsmentioning
confidence: 99%
See 4 more Smart Citations
“…Of the 13 articles, four were prospective observational cohort studies, one was a retrospective case-control study, and the remaining eight were retrospective observational cohort studies (Appendix S1). [15][16][17][18][19][20][21][22][23][24][25][26][27] Over 12 years, there were 10,750 patients who underwent cutaneous surgery, with 1,312 of them performed on patients prescribed a DOAC. The mean participant age ranged from 68 to 78.8 years of age, with a male predominance (49.9-81.8%).…”
Section: Resultsmentioning
confidence: 99%
“…The included articles studied four areas: (1) complication rate in those who continued DOAC therapy, 15,16 (2) complication rate in those who ceased DOAC therapy prior to undergoing skin surgery, 17,18 (3) complication rate between patients who had their DOAC therapy ceased vs continued, 19 and (4) comparing complication rate in patients anticoagulated with a DOAC agent vs a control group not on a DOAC agent (Table 1). [20][21][22][23][24][25][26][27] Outcomes DOAC continuation Antia et al 15 evaluated 76 MMS on patients who were prescribed a DOAC, resulting in one mild bleeding complication in a person taking rivaroxaban (1.32%). Chang et al conducted 46 procedures in patients on DOAC therapy (41 on dabigatran and five on rivaroxaban).…”
Section: Resultsmentioning
confidence: 99%
See 3 more Smart Citations